NovaVive Inc.

What NovaVive Inc. does

NovaVive Inc. is a privately held Canadian animal health immunobiology company headquartered in Napanee, Ontario, founded in July 2014 by Graeme McRae, the former founder and Chairman Emeritus of Bioniche Life Sciences. In December 2014 the company acquired an advanced immunotherapeutic platform based on Mycobacterium Cell Wall Fraction (MCWF) technology from Bioniche Animal Health, including four registered veterinary products. NovaVive develops and commercializes MCWF-based immunotherapeutics that activate animals' innate and adaptive immune responses to fight bacterial infections and certain cancers without relying on traditional antibiotics. Its product portfolio includes Amplimune (treatment of E. coli K99 diarrhea in neonatal calves, metritis, mastitis and fertility management in dairy cattle), Settle (treatment of equine endometritis), Equimune (equine viral respiratory disease complex), and Immunocidin/Immunocidin Equine (intratumoral treatment of canine mammary tumors and equine sarcoid tumors). Several products carry OMRI organic-production listings, and the platform includes a globally licensed MCNA (Mycobacterial Cell Wall-Nucleic Acid Complex) asset with Phase III applications in human bladder cancer.

The company operates a distributor-led go-to-market model, selling to veterinarians across five approved jurisdictions (USA, Canada, Australia, New Zealand, and UAE). Geographic commercialization is executed through channel partners: AABEX Animal Health handles U.S. market access, Agilis Vet Ltd distributes in New Zealand, and Hoken Biotechnology serves as exclusive distributor in China, Thailand, Malaysia, and Indonesia. NovaVive supports adoption through scientific publications, peer-reviewed clinical research (with institutions such as Colorado State, Iowa State, University of Minnesota, University of Kentucky, and CSIRO Australia), and presence at major veterinary conferences including World Buiatrics Congress, ACVIM, AABP, and Bain Fallon Memorial Lectures. Revenue is generated from product sales to veterinary practices serving dairy and beef cattle producers, horse owners and breeders, and companion animal oncology clinics; the company is financed through internal investment, product revenues, and the NovaVive Limited Partnership.

Name

NovaVive Inc.

Legal name

NovaVive Inc.

Website

https://novavive.ca

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

NovaVive Inc. is a private Canadian animal health company that develops and commercializes proprietary Mycobacterium Cell Wall Fraction (MCWF) immunotherapeutics for cattle, horses, and dogs, selling through regional distributors to veterinarians across the USA, Canada, Australia, New Zealand, and UAE.

Ownership category

akta.pro rank

Product category

Veterinary Immunotherapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Veterinary Services (54194)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Biologics & Immunotherapies (Non-vaccine) (HLAMAEAK)

akta.pro secondary industries

Livestock & Production Animal Therapeutics (Rx) (HLAMAEAB), Antimicrobials & Anti-infectives (HLAMAEAE), Veterinary Pharmacy, Vaccine & Biologics Services (AFAEANAK)

Keywords

• Veterinary immunotherapeutics
• Animal health biologics
• Antibiotic alternatives
• Livestock health products
• Companion animal therapeutics

Headquarters

HQ city

Napanee

HQ country

Canada

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Personnel, Technology or R&D, Marketing or Sales, Supply Chain, Others

Revenue model

1. Veterinary Immunotherapeutic Products: NovaVive generates revenue through the sale of its MCWF-based immunotherapeutic products to veterinarians for use in cattle, horses, and dogs. Products are sold directly to veterinarians who then administer or prescribe to animal owners. The company has 5 regulator-approved products in the USA, 4 in Canada, 3 in New Zealand, 2 in Australia, and 2 in UAE.

Go-to-market motion1 record

Distribution channels5 records

Marketing channels4 records

Core offering

NovaVive develops, registers and sells a line of Mycobacterium Cell Wall Fraction (MCWF)-based immunotherapeutic products (Amplimune, Settle, Equimune, Immunocidin, Immunocidin Equine) that act as antibiotic alternatives or targeted immunotherapies for cattle, horses, and dogs. The company sells these regulator-approved biological products directly to veterinarians across the USA, Canada, Australia, New Zealand, and UAE, who then administer or prescribe them to livestock producers and companion animal owners.

Differentiator

Problem solved

Functional benefit

Brands

• Amplimune: Immunotherapeutic for E. coli K99 diarrhea in neonatal calves, also used for metritis and mastitis prevention in dairy cows
• Settle
• Immunocidin
• Immunocidin Equine
• Equimune

Products and services

• Amplimune MCWF-based immunotherapeutic administered to neonatal calves to reduce clinical signs and mortality associated with E. coli K99 diarrhea, and used in dairy cows to reduce metritis and mastitis and improve pregnancy rates; OMRI listed for organic production. Sold to veterinarians.
• Settle MCWF immunotherapy for the treatment of equine endometritis caused by Streptococcus zooepidemicus. Approved for IV injection or intrauterine infusion, compatible with natural breeding or AI and conventional treatments. Sold to equine veterinarians.
• Equimune Immunotherapeutic registered in the U.S., Australia, and New Zealand for the treatment of viral equine respiratory disease complex (ERDC), including EHV-1. Sold to equine veterinarians for prevention and treatment of viral respiratory infections.
• Immunocidin Equine Intratumoral MCWF immunotherapeutic for the treatment of equine sarcoid tumors, administered by equine veterinarians. Contains mycobacterial cell walls complexed with bacterial DNA and RNA that induces apoptosis in tumor cells.
• Immunocidin MCWF (MCNA) formulation for intratumoral treatment of canine mammary tumors and other companion animal cancers; based on mycobacterial cell walls complexed with bacterial nucleic acids (DNA and RNA) that induce apoptosis in cancer cells. Sold to veterinary oncologists and general practice veterinarians.

Quantifiable outcome

• 68.6% reduction in clinical mastitis incidence (6.3% vs 19.7% in control)
• +6 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Twelve partnerships are on record, tiered minor and core.

• Gluck Equine Research Center (University of Kentucky)minorStrategic or Co-development Partner · 22 November 2022Collaborated on study demonstrating positive effect of Settle on endometrial cups. Research presented at International Symposium on Equine Reproduction.
• Rood & Riddle Equine HospitalminorStrategic or Co-development Partner · 22 November 2022Collaborated with Gluck Equine Research Center on endometrial cups study with Settle immunotherapy. Dr. Maria Schnobrich presented findings.
• CSIRO AustraliaminorStrategic or Co-development Partner · 10 March 2022Conducted safety study with Amplimune in young feedlot cattle published in Australian Veterinary Journal. Study concluded Amplimune can be safely administered at various doses and routes.
• Colorado State UniversityminorStrategic or Co-development Partner · 15 September 2021Conducted research study on peripartal administration of MCWF (Amplimune) on health and fertility of Holstein cows under organic-certified management. Published in Journal of Animal Science.
• Agilis Vet LtdcoreChannel Partner/ Reseller/ Distributor · 2 September 2020New Zealand distributor for Amplimune. Agilis is a veterinarian-owned company supplying production animal health products to veterinary clinics throughout New Zealand.
• University of MinnesotaminorStrategic or Co-development Partner · 16 September 2019Conducted 1,360-calf study showing economic benefit of Amplimune administered in calves prior to shipment. Dr. Luciano Caixeta presented findings at AABP conference.
• Iowa State University College of Veterinary MedicinecoreStrategic or Co-development Partner · 19 February 2019Clinical study evaluating Immunocidin in combination with doxorubicin chemotherapy vs doxorubicin alone in dogs with splenic hemangiosarcoma post-splenectomy. 66 dogs to be recruited across 10 oncology clinics.
• AABEX Animal HealthcoreChannel Partner/ Reseller/ Distributor · 17 August 2018Marketing services agreement for U.S.A. AABEX is founded by Mark Hill, former Senior Sales Director for Merial Ltd. U.S. Large Animal Division. Will work to identify, assess and execute market opportunities for NovaVive's five USDA-approved immunotherapeutics.
• Iowa State University College of Veterinary MedicinecoreStrategic or Co-development Partner · 4 December 2017Clinical study with Immunocidin Equine evaluating efficacy and safety in treatment of sarcoids and squamous cell carcinoma. Dr. Stephanie S. Caston is Principal Investigator. 60 horses to be enrolled.
• Hoken Biotechnology (Beijing) Co., Ltd.coreChannel Partner/ Reseller/ Distributor · 7 September 2017Exclusive distribution agreement for Amplimune in China, Thailand, Malaysia, and Indonesia. Hoken will conduct clinical studies to support regulatory submissions and serve as sales and marketing agent. Two parties agreed to negotiate a Joint Venture to commercialize and/or manufacture the product.
• Dr. Philip Bergman, DACVIM-OncologyminorStrategic or Co-development Partner · 19 April 2016Part of canine cancer clinical development plan. Dr. Bergman is Medical Oncologist and Director of Clinical Studies for VCA, past President of Veterinary Cancer Society.
• Dr. Craig Clifford, DACVIMminorStrategic or Co-development Partner · 19 April 2016Part of canine cancer clinical development plan. Dr. Clifford is Medical Oncologist and Director of Clinical Studies for Hope Veterinary Specialists.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Virbac: Independent global animal health company with strong positions in companion-animal specialty and livestock pharmaceuticals. Comparable in product mix (immunotherapeutics, specialty biologics) and species coverage.
• Phibro Animal Health: Animal health and mineral nutrition company serving livestock producers globally. Comparable on cattle-focused health-product positioning and on positioning against antibiotic resistance via non-antibiotic alternatives.
• Elanco Animal Health: Broad-line animal health company with companion-animal therapeutics and livestock pharmaceuticals, including oncology. Elanco's acquisition of Aratana Therapeutics (a pet-immunotherapy biotech) makes it a close comparability reference for NovaVive's canine and equine oncology pipeline.
• Merck Animal Health: Division of MSD offering vaccines, anti-infectives, and pharmaceuticals across production animals and companion animals. Highly comparable on product breadth, species coverage, and global distribution reach.
• Vetoquinol: Independent animal health company focused on livestock and companion-animal pharmaceuticals across Europe, North America, and Asia-Pacific. Comparable on specialty pharmaceutical positioning and species diversification.
• Zoetis: Largest pure-play animal health company globally, with deep portfolios across livestock pharmaceuticals, vaccines, and companion-animal therapeutics including oncology. Comparable as the dominant incumbent NovaVive competes against for veterinary mindshare and distribution.
• Boehringer Ingelheim Animal Health: Major animal health player with biologic, vaccine, and pharmaceutical portfolios across livestock and pets. Competitor in the antibiotic-alternative and immunotherapeutic categories, with materially greater R&D and commercial resources.

Direct peers

• Ceva Santé Animale: Global animal health company with a strong focus on veterinary biologics, vaccines, and immunotherapeutics across livestock and companion animals. Ceva operates in similar species (cattle, equine, companion animals) and competes in the immunotherapeutic/biologic category that defines NovaVive's core.

Emerging players

• Zomedica Pharmaceuticals: Small-cap veterinary specialty pharmaceutical company developing therapeutics and diagnostics for companion animals. Comparable as a similarly sized, narrowly focused animal-health biotech competing for the same specialty veterinary channel.
• Aratana Therapeutics: Specialty companion-animal therapeutics developer focused on veterinary oncology and immunology (now part of Elanco). Direct comparability in canine/equine immunotherapeutics and veterinary oncology pipeline strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/novaviveequine

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NovaVive Inc.